Enzymatic hydroxylation process for the preparation of HMG-COA reductase inhibitors and intermediates thereof

Abstract: An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.

Description: The present invention relates to an enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors. The present invention provides a method for the preparation of a compound of the formula I: its partially or completely hydrogenated analogs or a salt thereof, wherein R is alkyl or aryl; Z is the open chain moiety or the lactone ; and R 2 is hydrogen, alkyl, ammonium, alkyl-ammonium or alkali metal; comprising the step of contacting a compound of the formula II: a partially or completely hydrogenated analog or a salt thereof, wherein R, Z and R 2 are as defined for formula I, with a microorganism, or with an enzyme derived from, or having the structure of an enzyme derived from said microorganism, which is capable of catalyzing the hydroxylation of said compound of the formula II or salt thereof to yield said compound of the formula I or salt thereof, and effecting said hydroxylation; where said microorganism is selected from the genera Amycolata, Saccharopolyspora, Amycolatopsis, Saccharothrix or Gilbertella , provided that when the compound of formula II is compactin or R is alkoxyalkyl or alkyl substituted by protected hydroxy, the microorganism is not Amycolata . The enzymatic hydroxylation process of the present invention provides an efficient means for obtaining compounds of the formula I, which may themselves exhibit HMG-CoA reductase inhibitory activity, and/or which may be used as intermediates in the preparation of other HMG-CoA reductase inhibitors. Reduction or elimination of by-products may be achieved by employing the hydroxylation method of the present invention, which method may also be conducted under mild reaction conditions. Known from EP-A-0 609 058, which is considered prior art under the terms of Article 54(3) and (4) EPC, are processes for the enzymatic hydroxylation of compounds of formula II above where R is alkoxyalkyl or alkyl substituted by protected hydroxy and where the microorganism can be Amycolata, Nocardia or Streptomyces . U.S. Patent No. 4,346,227 discloses the enzymatic hydroxylation of compactin using various microorganisms among which are microorganisms of the genus Streptomyces. Similarly, U.S. Patent No. 4,537,859 discloses such process for hydroxylation of compactin using microorganisms of the genus Nocardia . The method of the present invention is described further as follows. Definitions The terms "enzymatic process" or "enzymatic method" as used herein denote a process or method employing an enzyme or microorganism. The term "alkyl" as used herein, alone or as part of another group, denotes both straight and branched chain, optionally substituted hydrocarbons containing 1 to 12 carbons in the normal chain, preferably 1 to 6 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like. Exemplary substituents may include one or more groups selected from the following: halo (especially chloro), trihalomethyl, alkoxy (for example, where two alkoxy substituents form an acetal), aryl such as unsubstituted aryl (e.g., phenyl), alkyl-aryl or haloaryl, cycloalkyl such as unsubstituted cycloalkyl or alkyl-cycloalkyl, hydroxy or protected hydroxy, carboxyl, alkyloxycarbonyl, alkylamino, dialkylamino such as dimethylamino, alkylcarbonylamino such as acetylamino, amino, arylcarbonylamino, nitro, cyano, thiol, or alkylthio. Preferred alkyl substituents are hydroxy groups. The term "alkenyl" as employed herein, alone or as part of another group, denotes optionally substituted straight or branched chain hydrocarbon groups as described above for alkyl, further containing at least one carbon to carbon double bond. The term "cycloalkyl" as employed herein, alone or as part of another group, denotes an optionally substituted, saturated homocyclic carbon ring system, preferably containing from 1 to 3 rings and from 3 to 12, preferably from 3 to 8, carbons per homocyclic ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, and adamantyl. Exemplary optional substituents include one or more alkyl groups as described above, or one or more of those groups described above as alkyl substituents. The term "aryl" as used herein denotes monocyclic or bicyclic substituted or unsubstituted aromatic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Exemplary substituents (preferably three or fewer) include one or more of the following groups: alkyl such as unsubstituted alkyl, haloalkyl or cycloalkylalkyl, halogen, alkoxy such as unsubstituted alkoxy or haloalkoxy, hydroxy, aryl such as phenyl or halophenyl, aryloxy such as phenoxy, alkylcarbonyloxy or aroyloxy, allyl, cycloalkyl, alkylamino, dialkylamino, amido such as alkylcarbonylamino or arylcarbonylamino, amino, nitro, cyano, alkenyl, thiol, alkylcarbonyl, or arylcarbonyl, or methylenedioxy where the methylene group may be substituted by lower alkyl group(s) (that is, alkyl groups as described above having 1 to 6 carbon atoms), arylalkenyl group(s), and/or alkylthio group(s). The terms "halo" or "halogen" as used herein denote chlorine, fluorine, bromine or iodine. The term "salt(s)" as employed herein refers to acidic and/or basic salts formed with inorganic and/or organic bases. The nontoxic, pharmaceutically acceptable salts are preferred. Exemplary pharmaceutically acceptable salts include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium as well as those salts formed from amines such as ammonia, ethylene-diamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-yl-methylbenzimidazole, diethylamine, piperazine and tris(hydroxymethyl)-aminomethane. The term "pharmaceutically acceptable cation" denotes a positive counterion forming a pharmaceutically acceptable salt, such as those described above. The term "ATCC" as used herein refers to the accession number of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, an organism depository. Starting Materials Compounds of the formula II to be employed in the hydroxylation method of the present invention may be obtained by methods known to the skilled artisan. Such compounds are disclosed, for example, in U.S. Patent No. 4,450,171. Preferred Compounds Compounds of the formula I having the following formula Ia are preferred: its partially or completely hydrogenated analogs or alkali metal salts thereof, wherein R is alkyl and R 2 is as defined in formula I. A particularly preferred example is: its partially or completely hydrogenated analogs or alkali metal salts thereof. Compounds of the formula II having the following formula IIa are preferred for use as the starting material: its partially or completely hydrogenated analogs or alkali metal salts thereof, wherein R is alkyl and R 2 is as defined in formula II. A particularly preferred example is its partially or completely hydrogenated analogs or alkali metal salts thereof. Compounds of the formula I, or any compound described herein, in which one or more of the double bonds is absent, may be obtained by hydrogenating the corresponding compound in which such bonds are present according to methods known to the skilled artisan. Any of the products of the present method may be isolated and purified by known methodologies such as by filtering off cells or cellular materials where appropriate, extraction, crystallization, thin layer or column chromatography, high performance liquid chromatography and the like. The above structures shown for methyl compactin and methyl pravastatin are referred to herein as the acid form of these compounds. Where the carboxyl group of these compounds is in the alkali metal salt form, the compounds are referred to herein as the salt form. As discussed below, the use of an aqueous medium is preferred in conducting the hydroxylation method of the present invention. It is therefore preferred to prepare, or to employ as starting materials, those compounds in which Z is the open chain moiety as defined above since such compounds are relatively more water soluble than the corresponding compounds in which Z is a lactone moiety. Compounds of the formula II in which Z is a lactone moiety may, for example, be hydrolyzed to the open chain form prior to use in the process of the present invention. Enzymes and Microorganisms Exemplary species suitable for use in the present invention include Amycolata autotrophica such as ATCC 35204, Amycolatopsis mediterranei such as ATCC 21411, Saccharothrix australensis such as ATCC 31497, Gilbertella persicaria such as ATCC 38591, Saccharopolyspora hirsuta such as ATCC 27875, 27876 or 20501 and Saccharopolyspora erythraea such as ATCC 11635. Particularly preferred are Amycolata autotrophica such as ATCC 35204 and Saccharopolyspora hirsuta such as ATCC 20501. With respect to the use of microorganisms, the method of the present invention may be carried out using any microbial cellular material having the ability to catalyze the conversion as described herein. The cells may be used in the form of intact wet cells or dried cells such as lyophilized, spray-dried or heat-dried cells. Cells may also be used in the form of treated cell material such as ruptured cells or cell extracts. The cells or cellular materials, such as isolated fungal mycelia, may be employed in the free state or immobilized on a support such as by physical adsorption or entrapment. One or more species of microorganism may be employed when carrying out the instant process. The method of the present invention may be carried out subsequent to the growth of the microorganism(s) employed, for example, by growing the microorganism(s) either in the presence or absence of a compound of the formula II starting material, harvesting and, preferably, washing (e.g., with water) the microbial materials, and then contacting the microbial materials obtained with the compound of the formula II starting material. The method of the present invention may also be carried out by in situ fermentation and reaction, that is, reaction in the presence of actively growing microorganisms. The reaction may be conducted under quiescent (static) conditions, or by employing agitation, Agitation, such as shake-flask culture or aeration and agitation, is preferably employed when the compound of the formula II starting material is added to actively growing cultures. In such cases, an anti-foaming agent may be employed. The growth of microorganisms may be achieved by the skilled artisan, for example, by the use of an appropriate medium containing nutrients such as carbon and nitrogen sources and trace elements. Exemplary assimilable carbon sources include glucose, glycerol, maltose, dextrin, starch, lactose, sucrose, molasses, soybean oil, cotton seed oil, etc. Exemplary assimilable nitrogen sources include soybean meal, peanut meal, cotton seed meal, fish meal, corn steep liquor, peptone, rice bran, meat extract, yeast, yeast extract, sodium nitrate, ammonium nitrate, ammonium sulfate, etc. Inorganic salts such as sodium chloride, phosphates, calcium carbonate, etc., may be added to the culture medium. A minor amount of a metal salt or heavy metal may also be added. The same or different media may be employed at various stages of the growth of the microorganisms. Preferred media for the growth of microorganisms are those described in the examples herein, which media may be employed for the growth of any microorganism employed in the method of the present invention. Enzymes, when employed, are preferably derived from the aforementioned microorganisms, or they may be synthetically or otherwise prepared. For example, they may be derived from genetically engineered host cells. The use of the genetically engineered host cells themselves , or cells which have otherwise been modified, is also contemplated where such cells are capable of producing enzymes having the structure of enzymes derived from the above recited genera of microorganisms. Reaction Conditions The method of the present invention may be conducted in an aqueous medium, such as a buffered aqueous medium. The aqueous phase is conveniently water, preferably deionized water, or a suitable aqueous buffer solution, especially a phosphate buffer solution. Use of an aqueous medium is preferred for the present hydroxylation method. The reaction in the present invention may also be conducted in an organic medium or in a medium which is a mixture of an organic medium and an aqueous medium. Use of an organic or organic/aqueous medium may enhance solubilization of the less water soluble compounds of the formula II starting materials, such as those where Z is a lactone moiety. Less water soluble starting materials may, for example, be dissolved in an organic solvent such as methyl or ethyl alcohol, and the solution added to an aqueous medium for conversion. Liquids forming such organic media may be immiscible in water or, preferably, may be miscible in water. Exemplary organic media include toluene, hexane, benzene, acetone, dimethylsulfoxide, cyclohexane, xylene, trichlorotrifluoroethane, alkanols such as methyl or ethyl alcohol or butanol, and the like. It is preferred that the starting material is dissolved, for example, in water or an alcohol, prior to addition to the reaction medium. The reaction medium preferably contains between about 0.5 to about 3 mg of a compound of the formula II starting compound per ml of liquid medium. The pH of the reaction medium is preferably between about 6.0 and about 7.5. To carry out the hydroxylation reaction of the present invention, water or an organic alcohol, for example, an alkanol such as methyl or ethyl alcohol, may be added. It is preferred to employ these materials in an amount providing a molar excess, preferably a large molar excess, based on the compound of formula II starting material. The amount of microbial cells added, where employed in the present process, is preferably an amount ranging from about 10 to about 1000 mg per mg of the compound of formula II starting material. The amount of enzyme added, where employed in the present process, is preferably an amount ranging from about 1 to about 100 mg per mg of the compound of formula II starting material. The reaction medium is preferably held at a temperature between about 27 and 40°C, and is most preferably held between about 28 and about 34°C. The reaction time can be appropriately varied depending upon the amount of enzyme produced by the microbial cells, or used per se , and its specific activity. Typical reaction times are between about 2.5 hours and about 72 hours. Reaction times may be reduced by increasing the reaction temperature and/or increasing the amount of enzyme added to the reaction solution. Preparation of HMG-CoA Reductase Inhibitors HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase, EC 1.1.1.34) is a key enzyme in cholesterol biosynthesis. Inhibitors of this enzyme find utility as anticholesterolemic agents, that is, in lowering or maintaining plasma cholesterol levels. In addition to the treatment and prevention of hypercholesterolemia, HMG-CoA reductase inhibitors find utility in the treatment and prevention of atherosclerosis, hyperlipoproteinaemia, and/or hyperlipidemia. Compounds of the formula II described above may themselves exhibit HMG-CoA reductase inhibiting activity (e.g., methyl compactin), and/or may be employed as intermediates in the preparation of other compounds having HMG-CoA reductase inhibiting activity. In the latter case, the present invention further provides a method wherein hydroxylation is conducted according to the above-described method of the present invention and, subsequently, the hydroxylated product so formed is employed in the preparation of an HMG-CoA reductase inhibitor (e.g., groups are deprotected, added or otherwise modified thereon). Preferably, the inhibitor so prepared has enhanced HMG-CoA reductase inhibiting activity relative to any such activity the hydroxylated product from which it is prepared may possess. HMG-CoA reductase inhibitors obtained according to the method of the present invention may, for example, be administered to mammals, particularly humans, by modes and in dosages selected according to methods known to the skilled artisan. A particularly preferred method for the preparation of an HMG-CoA reductase inhibitor of the present invention is that comprising the steps of: (A) hydroxylating a compound of the formula IIa , wherein R is and R 2 is H, or a salt thereof with Amycolata autotrophica (ATCC 35204) or Saccharopolyspora hirsuta subspecies kobensis (ATCC 20501) to yield methyl pravastatin having the structure: or the alkali metal, especially sodium or lithium, salt thereof. The following Examples illustrate preferred embodiments of the present invention, and are not intended to limit the scope or spirit of the instant claims. The components of the media employed in these Examples are as follows. Medium Media Compositions F7 malt extract 10 g/L, yeast extract 10 g/L, peptone 1 g/L, dextrose 20 g/L, distilled water to one liter, pH adjusted to 7.0 before sterilization by autoclaving K28 Pharmamedia 25 g/L, cerelose 69 g/L, CaCO 3 9 g/L, K 2 HPO 4 0.1 g/L, tap water to one liter, pH adjusted to 6.8 - 7.0 before sterilization by autoclaving F4 tryptone 5 g/L, malt extract 3 g/L, glucose 10 g/L, yeast extract 3 g/L, distilled water to one liter, sterilize in autoclave F46 glycerol 10 g/L, maltose 40 g/L, toasted Nutrisoy flour 30 g/L, peptone 10 g/L, spray dried corn steep liquor 10 g/L, MgSO 4 ·7H 2 O 0.5 g/L, tap water to one liter, pH adjusted to 5.3 before sterilization by autoclaving M124 cerelose 10 g/L, NZ Amine B 15 g/L, yeast extract 10 g/L, NaCl 5 g/L, CaCO 3 1 g/L, tap water to one liter, pH adjusted to 6.8 - 7.0 before sterilization by autoclaving Mueller-Hinton Broth (Difco brand) beef infusion 300 g/L, casamino acids, technical 17.5 g/L, starch 1.5 g/L, suspended in one liter distilled or deionized water and heated to boiling to dissolve completely, final pH 7.4 Trypticase Soy Broth, BBL brand trypticase peptone 17 g/L, phytone peptone 3 g/L, NaCl 5 g/L, K 2 HPO 4 2.5 g/L, dextrose 2.5 g/L, distilled water to one liter, sterilize in autoclave Y17 yeast nitrogen base 6.7 g/L, glucose 50 g/L, Sigma adenine HCl 0.09 g/L, Sigma 1-tyrosine 0.06 g/L, heat to boil and mix Difco casamino acids 2 g/L, agar 20 g/L, distilled water to one liter, sterilize in autoclave Example 1 One frozen vial of Amycolata autotrophica (ATCC 35204) and one frozen vial of Saccharopolyspora hirsuta subspecies kobensis (ATCC 20501) were thawed and used to inoculate separate 500 ml flasks containing 100 ml each of medium F4. Each flask was placed on a shaker at approximately 280 rpm, at 25°C, and shaken for 72 hours. Aliquots of 2.5 ml apiece of the 72 hour A . autotrophica culture broth were used to inoculate six 250 ml flasks containing 50 ml of medium F7 and six 250 ml flasks containing 50 ml of medium K28. Similarly, aliquots of 2.5 ml apiece of the 72 hour S. hirsuta culture broth were used to inoculate six 250 ml flasks containing 50 ml of medium F7 and six 250 ml flasks containing 50 ml of medium K28. Accordingly, there were 24 flasks in total. All 24 flasks were placed on a shaker and shaken at approximately 280 rpm at 25°C. After 24 hours of shaking, 1 ml of filter-sterilized 5 mg/ml methyl compactin salt solution was added aseptically to three F7 flasks and three K28 flasks of each culture. (Salt solution was prepared from the lactone by dissolving the lactone in a minimal volume of ethanol, adding about 15 ml of water [which produces some precipitate], adjusting the pH to about 11.8, incubating in a 65°C waterbath until the precipitate dissolved, and carefully bringing the pH down to 7.5. Distilled water was added to bring the calculated concentration to 5 mg/ml.) Two new flasks were added at this point, as one uninoculated flask of each medium was dosed with the salt to control for non-biological modifications. These flasks henceforth were treated the same as the inoculated flasks. Similarly, a sterile 500+ µg/ml dose of compactin was added to three F7 and three K28 flasks of each culture. Two new flasks were added, as one uninoculated flask of each medium was also dosed with compactin. (The purpose of the inoculated compactin flasks was to serve as positive controls, showing that hydroxylation of compactin was occurring normally. The uninoculated flasks served as controls for possible nonbiological alterations of substrate.) Shaking was resumed for an additional 24 hours. All flasks then received a second dose of the same salt with which they had been dosed previously. Shaking was again resumed for 24 hours, following which eight flasks were harvested (at time T 1 ), including one for each culture-medium-substrate combination. The broths from the harvested flasks were submitted for assay of substrate and hydroxylated product. Following an additional 24 hours of shaking, the remaining 20 flasks were harvested (at time T 2 ), including 10 methyl compactin salt samples and 10 compactin samples. The broths were submitted for appropriate substrate-product assay. The results are shown below: Culture Medium Compactin (µg/g) Pravastatin (µg/g) T 1 T 2 T 2 T 1 T 2 T 2 A. autotrophica F7 8.4 0 0 474 475 503 K28 4.6 0 0 470 575 512 S. hirsuta F7 842 127 122 347 775 753 K28 412 0 0 675 750 762 None (control) F7 - 1857 - - 0 - K28 - 1806 - - 0 - Culture Medium Methyl Compactin (µg/g) Methyl Pravastatin (µg/g) T 1 T 2 T 2 T1 T 2 T 2 A. autotrophica F7 0 0 0 57.9 56.4 55.4 K28 0 0 0 59.8 62.4 66.7 S. hirsuta F7 1.7 0 0 71.5 77.1 82.9 K28 3.1 0 0 58.9 63.3 63.8 None (control) F7 - 96.5 - - 0 - K28 - 90.2 - - 0 - EXAMPLE 2 One frozen vial of Saccharapolyspora hirsuta subspecies kobensis (ATCC 20501) was thawed and used to inoculate a 500 ml flask containing 100 ml of medium F4. The flask was placed on a shaker at approximately 280 rpm, at 25°C, and shaken for 72 hours. Aliquots of the 72 hour broth were used to inoculate two 250 ml flasks containing 45 ml of medium K28. The two flasks were placed on a shaker and shaken at approximately 280 rpm at 25°C. After 24 hours of shaking, methyl compactin salt was dissolved in water to provide a solution which was filter-sterilized. A portion of this solution was added to one of the K28 flasks. Six hours later, an identical portion was added to the same flask. The second K28 flask also received a portion as did a third uninoculated K28 flask. All three flasks were placed on the shaker and shaking resumed for 18 hours. The first flask then received a third dose. Six hours later, the first flask received a fourth (and final) dose; the second flask received a second (and final) dose; and the uninoculated flask received a second (and final) dose. Following an additional 42 hours of shaking, the three flasks were harvested and all of the broths were submitted for assay of methyl compactin and methyl pravastatin. The results are shown below: Sample Methyl Compactin (µg/g) Methyl pravastatin (µg/g) Flask 1 0 284.8 Flask 2 0 251.5 No-cells control 418.6 0 EXAMPLE 3 One frozen vial each of Amycolata autotrophica (ATCC 35204), Streptomyces californicus (ATCC 15436) (reference example), Amycolata hydrocarbonoxydans (ATCC 15104), Amycolata mediterranei (ATCC 21411), Amycolatopsis fastidiosa (ATCC 31181) and Saccharopolyspora hirsuta subspecies kobensis (ATCC 20501) were thawed and used to inoculate 500 ml germinator flasks containing 100 ml of medium F7. All flasks were placed on a shaker at approximately 280 rpm, at 25°C, and shaken for 72 hours. 10 ml aliquots from each germinator flask were used to inoculate separate flasks each containing 120 ml of medium K28. All flasks were then returned to the shaker. After 24 hours, 500 µg/ml of filter sterilized compactin (acid form) was added to each flask. Again the flasks were returned to the shaker. 24 hours later, 15 ml aliquots were removed from each flask and frozen for later assay (T 1 ). A second 500 µg/ml dose of sterile acid-form compactin was added to each flask and the flasks were returned to the shaker. 24 hours after that, a second 15 ml aliquot sample was removed from each flask and frozen for later assay (T 2 ); and 24 hours after that, a final 15 ml aliquot was removed from each flask and frozen for later assay (T 3 ). All samples were thawed and submitted for assay. The results are shown in the tables below: Culture T 1 Compactin Pravastatin Conversion A.hydrocarbonoxydans 439 0 - A.mediterranei 21 142 28% A.fastidiosa 376 0 - S.hirsuta 40 201 40% Controls: A.autotrophica 68 110 22% S.californicus 0 75 15% Culture T 2 Compactin Pravastatin Conversion A.hydrocarbonoxydans 767 0 - A.mediterranei 15 282 28% A.fastidiosa 191 0 - S.hirsuta 19 399 40% Controls: A.autotrophica Trace 293 29% S.californicus 0 167 17% Culture T 3 Compactin Pravastatin Conversion A.hydrocarbonoxydans 812 0 - A.mediterranei 21 290 29% A.fastidiosa 711 0 - S.hirsuta Trace 394 39% Controls: A.autotrophica 3 276 28% S.californicus 2 157 16% EXAMPLE 4 46-hour cultures of Saccharopolyspora hirsuta subspecies kobensis (ATCC 20501) (grown at 28°C) and Amycolata autotrophica (ATCC 35204) (grown at 25°C) were used to inoculate flasks of various media (50 ml media/250 ml flask). 5 ml of innoculum were used per flask. S. hirsuta was inoculated into two separate flasks of each of the following media: F7, F46, K28, M124, Mueller Hinton, trypticase soy broth (TSB) and Y17. One flask of each medium was placed on a shaker at approximately 280 rpm, at 25°C, and another flask of each medium was placed on a shaker at approximately 280 rpm, at 28°C. An additional flask each of F7 medium and K28 medium was inoculated and placed in a water bath shaker at 32°C. A. autotrophica was inoculated into two separate flasks each of F7 medium and K28 medium. One inoculated flask of each medium was placed on a shaker at approximately 280 rpm., at 25°C, and one inoculated flask of each medium was placed on a shaker at approximately 280 rpm, at 28°C. After 24 hours, a 500 µg/g dose of filter sterilized compactin (acid form) was added to each flask. The flasks were returned to the shakers at the same temperature. 24 hours later, a 10 ml aliquot was removed from each flask and frozen for later assay (T 1 ). A second 500 µg/g dose of sterile acid-form compactin was added to each flask and the flasks were again returned to the shakers at the same temperature. After an additional 48 hours, a second 10 ml aliquot was taken (T 2 ). The T 1 samples were thawed and submitted with the T 2 samples for assay. The results are shown in the table below: EXAMPLE 5 67-hour cultures of various microorganisms grown in F4 medium at 25°C were used to inoculate 250 ml flasks containing 50 ml of medium F7 and 250 ml flasks containing 50 ml of medium K28. 5 ml of inoculum were used per flask. The organisms used were Cellulomonas cellulans (ATCC 12830) (reference example), Oerskovia xanthineolytica (ATCC 27402) (reference example), Promicromonospora citrea (ATCC 15908) (reference example), Saccharomonospora viridis (ATCC 15736) (reference example), Saccharopolyspora hirsuta (ATCC 27875), Saccharothrix australensis (ATCC 31497) and Streptomyces halstedii (ATCC 13449) (reference example). Saccharomonospora viridis and S. hirsuta (ATCC 27875) conversion flasks were placed on a shaker at approximately 280 rpm, at 28°C; the other cultures were placed on a shaker at approximately 280 rpm, at 25°C. A Saccharopolysporoa hirsuta subspecies kobensis (ATCC 20501) control was used for both 25°C and 28°C. After 24 hours, a 500 µg/g dose of compactin was added to each flask. 24 hours later, a second 500 µg/g dose of compactin was added to each flask. After 96 hours, a 15 ml aliquot was taken from each flask and frozen at -50°C for later assay. The samples were thawed and submitted for assay. The results are shown in the table below: Culture/Medium Temp. Compactin Pravastatin Conversion Ratio Pravastatin: by-products C. cellulans /F7 25°C 1107 0 - - C. cellulans /K28 25°C 1072 0 - - Oerskovia xanthineolyt. /F7 25°C 1116 0 - - Oerskovia xanthineolyt . /K28 25°C 688 0 - - Promicro . citrea /F7 25°C 1119 0 - - Promicro . citrea /K28 25°C 1309 0 - - Saccharothrix austral ./F7 25°C 63 473 43% 3.1 : 1 Saccharothrix austral ./K28 25°C 0 465 42% 4.6 : 1 Streptomyces halsted ./F7 25°C 887 0 - - Streptomyces halsted ./K28 25°C 1114 0 - - Saccpolysp . hirsuta ATCC 20501/F7 25°C 180 532 48% 9.4 : 1 Saccpolysp . hirsuta ATCC 20501/K28 25°C 73 511 46% 9.2 : 1 F7 blank 25°C 1281 0 - - K28 blank 25°C 1208 0 - - Saccharomon . viridis /F7 28°C 1213 0 - - Saccharomon . viridis /K28 28°C 1147 0 - - Saccharopoly . hirsuta ATCC 27875/F7 28°C 515 92 8% 1.6 : 1 Saccharopoly . hirsuta ATCC 27875/K28 28°C 410 194 18% 2.0 : 1 Saccharopoly . hirsuta ATCC 20501/F7 28°C 35 565 51% 12.8 : 1 Saccharopoly hirsuta ATCC 20501/K28 28°C 44 520 47% 8.7 : 1 EXAMPLE 6 Eight ATCC Mucorales fungi and one Staurophoma sp. ATCC 14288 were inoculated from well-grown slants into germinator flasks of medium F4 (100 ml F4/500 ml flasks) and placed on a slow shaker (about 200 rpm) at 25°C. The eight Mucorales fungi were Absidia ramosa (ATCC 11613), Circinella muscae (ATCC 16008), Cunninghamella echinulata var. echinulata (ATCC 36190), Cunninghamella echninulata var. elegans (ATCC 8688A), Gilbertella persicaria (ATCC 38591), Rhizomucor miehei (ATCC 26912), Rhizopus oligosporus ( ATCC 22959) and Rhizopus stolonifer (ATCC 14037). The fungi other than Gilbertella persicaria (ATCC 38591) are reference examples. After 72 hours of shaking, the growth in all the germinator flasks looked good except for the C . echinulata var. echinulata broth which was one large solid fungal mass. This was discarded. The seven remaining Mucorales flasks, and the one Staurophoma flask, were each used to inoculate bioconversion flasks (containing 50 ml medium per 250 ml flasks) of medium F7 and of medium K28. 2 ml of inoculum were used per flask. All flasks were placed on a regular speed (about 280 rpm) shaker at 25°C. After 24 hours, all flasks received 500 µg/ml dose of compactin, including two uninoculated flasks, one each of media F7 and K28. All flasks were returned to the shaker at 280 rpm and 25°C. After an additional 24 hours, all flasks received a second 500 µg/ml dose of compactin and were then returned to the shaker. Forty-eight hours later, samples of 15 to 20 ml were taken from each flask and assayed. The results were as follows: Gilbertella persicaria F7 - compactin 621 µg/g; pravastatin 274 µg/g; pravastatin:by-products ratio 2.3:1; and K28 - compactin 822 µg/g; pravastatin 54 µg/g; pravastatin:by-products ratio 3.4:1. Two of the other cultures showed, at best, trace levels of pravastatin ( Absidia and Rhizopus oligosporus ). All the others were negative for pravastatin. EXAMPLE 7 Saccharopolyspora hirsuta subspecies kobensis (ATCC 20501) inocula that were two days, three days and four days old in F4 medium (100 ml F4 medium per 500 ml flask, each inoculated with a frozen vial) were used to inoculate bioconversion flasks of medium K28 (50 ml K28 per 250 ml flask). Three flasks of medium K28 were inoculated from each germinator flask, using 5 ml of inoculum. In addition, inoculum from the three day old germinator flask was used to inoculate K28 medium flasks in triplicate with different volumes of inoculum. Specifically, 0.25 ml, 1.0 ml, 2.5 ml, 7.5 ml and 10 ml volumes were used. All flasks were placed on a shaker at approximately 280 rpm, and 28°C. After 24 hours, a 500 µg/ml dose of compactin sodium salt was added to each flask. After an additional 24 hours, 1,000 µg/ml compactin sodium salt dose was added to each flask. Forty-eight hours later, 25 flasks were harvested and sent for assay. The results are as follows: Age of Inoculum Vol. and % Inoculum Compactin µg/g (Av. of 3) Pravastatin µg/g (Av. of 3) Conversion 48 hours 5 ml (10%) Trace 597 40% 72 hours 0.25 ml (0.5 %) 1084 138 9% 72 hours 1 ml (2%) 901 211 14% 72 hours 2.5 ml (5%) 224 692 46% 72 hours 5 ml (10%) Trace 676 45% 72 hours 7.5 ml (15%) 10 609 41% 72 hours 10 ml (20%) Trace 694 46% 96 hours 5 ml (10%) Trace 700 47% no inoculum - 1201 0 -

Claims: A method for the preparation of a compound of the formula I: its partially or completely hydrogenated analog or a salt thereof, wherein R is optionally substituted alkyl or optionally substituted aryl; Z is the open chain moiety or the lactone ; and R 2 is hydrogen, optionally substituted alkyl, ammonium, optionally substituted alkylammonium or alkali metal; comprising the step of contacting a compound of the formula II: a partially or completely hydrogenated analog or a salt thereof, wherein R, Z and R 2 are as defined for formula I, with a microorganism, or with an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation of said compound of the formula II or salt thereof to yield said compound of the formula I or salt thereof, and effecting said hydroxylation; where said microorganism is selected from the genera Amycolata, Saccharopolyspora , Amycolatopsis, Saccharothrix or Gilbertella , provided that when the compound of formula II is compactin or R is alkoxyalkyl or alkyl substituted by protected hydroxy, the microorganism is not Amycolata . The method of claim 1, wherein Z is said open chain moiety. The method of claim 2, wherein R is optionally substituted alkyl. The method of claim 1, wherein a compound having the following formula: or a partially or completely hydrogenated analog, or an alkali metal salt thereof, is prepared. The method of claim 1, wherein the compound of formula II is contacted with a microorganism. The method of claim 5, wherein said microorganism is Amycolata autotrophica ATCC 35204, Amycolatopsis mediterranei ATCC 21411, Saccharothrix australensis ATCC 31497, Gilbertella persicaria ATCC 38591, Saccharopolyspora hirsuta ATCC 27875, Saccharopolyspora hirsuta ATCC 27876, Saccharopolyspora hirsuta ATCC 20501 or Saccharopolyspora erythraea ATCC 11635. The method of claim 6, wherein said microorganism is Amycolata autotrophica ATCC 35204 or Saccharopolyspora hirsuta ATCC 20501. The method of claim 1, wherein the compound of formula II is dissolved in water or an alcohol before it is contacted with a microorganism or with an enzyme. The method of claim 1, wherein the step of contacting a compound of the formula II with a microorganism or with an enzyme is conducted in an aqueous medium. The method of claim 9, wherein about 0.5 to about 3 mg of a compound of the formula II is contained in each ml of aqueous medium. The method of claim 9, wherein the pH of the aqueous medium is between about 6.0 and about 7.5. The method of claim 9, wherein the temperature of the aqueous medium is between about 27 and 40°C. The method of claim 12, wherein the temperature of the aqueous medium is between about 28 and 34°C. The method of claim 1, wherein the step of contacting a compound of the formula II with a microorganism or with an enzyme continues for between about 2.5 and about 72 hours. The method of claim 1, wherein Z is the lactone. The method of claim 15, wherein the compound of the formula II is hydrolyzed before it is contacted with a microorganism or with an enzyme. The method of claim 1, wherein said compound of the formula I is employed in the preparation of an HMG-CoA reductase inhibitor. A method for the preparation of an HMG-CoA reductase inhibitor, comprising the step of hydroxylating a compound of the formula II, or salt thereof, according to the method of claim 1 to yield a compound of the formula I, or salt thereof.

Inventors: CINO PAUL M, DAVIS BRIAN L, SZARKA LASZLO, CINO, PAUL M., DAVIS, BRIAN L., SZARKA, LASZLO
Applicants: SQUIBB BRISTOL MYERS CO, BRISTOL-MYERS SQUIBB COMPANY
Application year: 1994
Main classification: C12P7
IPC codes: C12P7, A61P3, C12R1, C12P17, A61K31